Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017
(Thomson Reuters ONE) -
Mechelen, Belgium; 7 May 2017, 16.35 CET - Galapagos NV (Euronext & NASDAQ:
GLPG) announces the presentation of three posters from the Phase 2 FITZROY study
of the investigational agent filgotinib in Crohn's Disease, at Digestive Disease
Week(®) (DDW[1]) 2017 in Chicago, IL USA, held from 6-9 May. More information
can be found at www.ddw.org.
"Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior
anti-TNF exposure: subgroup analysis of the Phase 2 FITZROY study in moderate-
to-severe Crohn's disease" (Su1920) by Prof Geert D'Haens et al.
Subgroup analyses from the FITZROY Phase 2 study will be presented.
"Maintenance of clinical effect in patients with moderate-to-severe Crohn's
disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week
data analysis of the Phase 2 FITZROY study" (Su1930) by Prof Séverine Vermeire
et al.
A 20 week treatment analysis from the FITZROY Phase 2 study will be presented.
"Filgotinib (GLPG0634, GS-6034), a JAK-1 Selective Inhibitor, Significantly
Reduces Gut Tissue pSTAT3 in Crohn's Disease Patients" (Su1933) by Prof William
Sandborn et al.
An analysis of STAT3 activation in the FITZROY Phase 2 study will be presented.
These three posters from the previously reported FITZROY study will be presented
in the session titled "IBD: Controlled Clinical Trials in Humans" to be held on
7 May 2017 from 12:00 PM to 2:00 PM CT. As per DDW(®) policy, the embargo on
posters lifts at 9:30 AM CT on the date of presentation. The ePosters will be
made available to the public after June 6 2017 at the DDW(®) archive site,
ddw.scientificposters.com.
Galapagos and Gilead entered into a global collaboration for the development and
commercialization of filgotinib in inflammatory indications. Following on the
Phase 2 FITZROY results, filgotinib is currently being investigated in the
DIVERSITY Phase 3 program in Crohn's disease and in Phase 2 studies in small
bowel and fistulizing Crohn's disease. Furthermore, filgotinib is being
investigated in the SELECTION Phase 2b/3 study in ulcerative colitis, the FINCH
Phase 3 program in rheumatoid arthritis, and Phase 2 studies in CLE, Sjögren's
syndrome, ankylosing spondylitis (TORTUGA), and psoriatic arthritis (EQUATOR).
Filgotinib is an investigational drug and its efficacy and safety have not been
established.
For information about the studies with filgotinib: www.clinicaltrials.gov
For more information about filgotinib: www.glpg.com/filgotinib
About DDW
Digestive Disease Week(®) (DDW) is the largest international gathering of
physicians, researchers and academics in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the
American Association for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA) Institute, the American Society for
Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary
Tract (SSAT), DDW take place May 6-9, 2017, at McCormick Place, Chicago, IL. The
meeting showcases more than 5,000 abstracts and hundreds of lectures on the
latest advances in GI research, medicine and technology. More information can be
found at www.ddw.org.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-
clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 510 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Director Communications
Communications +31 6 53 591 999
+1 781 460 1784 communications(at)glpg.com
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir(at)glpg.com
Forward-Looking Statements
This release may contain forward-looking statements, including statements
regarding Galapagos' strategic ambitions, the anticipated timing of clinical
studies with filgotinib and the progression and results of such studies.
Galapagos cautions the reader that forward-looking statements are not guarantees
of future performance. Forward-looking statements involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in differences
are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities and regulatory approval
requirements (including that data from the ongoing and planned clinical research
programs may not support registration or further development of filgotinib due
to safety, efficacy or other reasons), Galapagos' reliance on collaborations
with third parties (including its collaboration partner for filgotinib, Gilead),
and estimating the commercial potential of Galapagos' product candidates. A
further list and description of these risks, uncertainties and other risks can
be found in Galapagos' Securities and Exchange Commission (SEC) filings and
reports, including in Galapagos' most recent annual report on form 20-F filed
with the SEC and subsequent filings and reports filed by Galapagos with the SEC.
Given these uncertainties, the reader is advised not to place any undue reliance
on such forward-looking statements. These forward-looking statements speak only
as of the date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based or that
may affect the likelihood that actual results will differ from those set forth
in the forward-looking statements, unless specifically required by law or
regulation.
--------------------------------------------------------------------------------
[1] The name, logo and acronym of Digestive Disease Week(®) are the exclusive
property of and are trademarked by DDW LLC.
DDW 2017:
http://hugin.info/133350/R/2102437/797310.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 07.05.2017 - 16:35 Uhr
Sprache: Deutsch
News-ID 540705
Anzahl Zeichen: 8701
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 388 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
